nach oben

International Urology and Nephrology

Erschienen in:

01.03.2015 | Urology - Original Paper

Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis

verfasst von: Wei Huang, Huantao Zong, Xin Zhou, Yong Zhang

Erschienen in: International Urology and Nephrology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We carried out a systematic review and meta-analysis to assess the efficacy and safety of imidafenacin for treating overactive bladder in adult.

Methods

A literature review was performed to identify all published randomized placebo-controlled trials of imidafenacin for the treatment of OAB. The search included the following databases: MEDLINE, EMBASE. The reference lists of retrieved studies were also investigated.

Results

Five publications involving a total of 1,428 patients were used in the analysis, which compared imidafenacin with propiverine and solifenacin. We found that imidafenacin was effective in treating OAB in our meta-analysis, which was similar to propiverine in its efficacy. The mean number of UI per week (the standardized mean difference (SMD) = 1.23, 95 % CI −0.19 to 2.65, p = 0.09), the mean number of urgency episodes per day (SMD = 0.26, 95 % CI −0.11 to 0.63, p = 0.17), the mean number of micturitions per day (SMD = 0.01, 95 % CI −0.30 to 0.31, p = 0.96), and the mean urine volume (ml) per micturition (SMD = −13.04, 95 % CI −20.45 to −5.62, p = 0.0006) indicated that imidafenacin was similar to propiverine in its efficacy. Mean OABSS (SMD = 0.48, 95 % CI −0.08 to 1.03, p = 0.09) indicated that imidafenacin was also similar to solifenacin in its efficacy. Besides, imidafenacin was better tolerated than propiverine in the safety, indicated by dry mouth (OR 0.73, 95 % CI 0.54–0.98, p = 0.04) and any adverse events (OR 0.63, 95 % CI 0.46–0.88, p = 0.006). Moreover, imidafenacin was also better tolerated than solifenacin in the safety, indicated by constipation (OR 0.21, 95 % CI 0.08–0.53, p = 0.001) and any adverse events (OR 0.33, 95 % CI 0.15–0.71, p = 0.004).

Conclusions

This meta-analysis indicates that imidafenacin was similar to propiverine or solifenacin in its efficacy for OAB and was better tolerated than propiverine or solifenacin in the safety for OAB. We conclude that imidafenacin is preferable to propiverine or solifenacin from a perspective of safety.

Abrams P, Kelleher CJ, Kerr LA et al (2000) Overactive bladder significantly affects quality of life. Am J Manag Care 6(Suppl):S580–S590PubMed

Kobelt G, Kirchberger I, Malone-Lee J (1999) Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 83:583–590CrossRefPubMed

Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336PubMed

Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766CrossRefPubMed

Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178CrossRefPubMed

Getsios D, El-Hadi W, Caro I et al (2005) Pharmacological management of overactive bladder. Pharmacoeconomics 23:995–1006CrossRefPubMed

Marinkovic SP, Rovner ES, Moldwin RM et al (2012) The management of overactive bladder syndrome. BMJ 344:38–44CrossRef

Andersson KE, Chapple CR, Cardozo L et al (2009) Pharmacological treatment of overactive bladder: report from the International Consultation on incontinence. Curr Opin Urol 19:380–394CrossRefPubMed

Sexton CC, Notte SM, Maroulis C et al (2011) Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 65:567–585CrossRefPubMed

10.

Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55:33–46 (discussion 50)CrossRefPubMed

11.

Madhuvrata P, Cody JD, Ellis G et al (2012) Which anticholinergic drugs for overactive bladder syndrome in adults? Cochrane Database Syst Rev 1:005429

12.

Kobayashi F, Yageta Y, Segawa M et al (2007) Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung 57:92–100PubMed

13.

Kobayashi F, Yageta Y, Yamazaki T et al (2007) Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arzneimittelforschung 57:147–154PubMed

14.

Murakami S, Yoshida M, Iwashita H et al (2003) Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urol Int 71:290–298CrossRefPubMed

15.

Homma Y, Yamaguchi T, Yamaguchi O (2008) A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 15:809–815CrossRefPubMed

16.

Homma Y, Yamaguchi O (2009) A randomized, double-blind, placebo- and propiverine controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 16:499–506CrossRefPubMed

17.

Higgins JPT, Green S, (eds) (2011) Cochrane handbook for systematic reviews of interventions, v.5.1 [updated March 2011]. Cochrane Collaboration Web site. http://www.cochrane-handbook.org/

18.

Zaitsu M, Mikami K, Ishida C et al (2011) Comparative evaluation of the safety and efficacy of long-term use of imidafenacin and solifenacin in patients with overactive bladder: a prospective, open, randomized, Parallel-group trial (the LIST Study). Adv Urol 2011:854697CrossRefPubMedCentralPubMed

19.

Yokoyama T, Koide T, Hara R et al (2013) Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study. Urol Int 90(2):161–167CrossRefPubMed

20.

Park C, Park J, Choo MS et al (2014) A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder. Int J Clin Pract 68(2):188–196CrossRefPubMed

21.

Takeda M, Takahashi S, Nishizawa O et al (2009) Imidafenacin, a novel anticholinergic, significantly improves both nocturia and sleep disorders in OAB patients: ePOCH (Evaluation of anticholinergics in Patients with Overactive bladder and nocturia for Care Health) study. Jpn J Urol Surg 22:53–60

22.

Nagaoka A, Sakurai T, Naito S et al (2011) Sleep disorders and HRQOL were significantly improved by imidafenacin, an anticholinergic agent, in OAB patients with nocturia. Jpn J Urol Surg 24:1649–1656

23.

Shimizu N, Minami T, Uemura H et al (2011) A study of the efficacy and safety of imidafenacin in younger and older elderly patients with overactive bladder. Jpn J Urol Surg 24:639–648

24.

Kuratsukuri K, Tsujimura A, Akino H et al (2012) Randomized controlled trial of nocturia in patients with benign prostatic hyperplasia with OAB using an alpha-blocker combined with a novel anticholinergic, imidafenacin In GOOD-NIGHT Study. Eur Urol (Suppl 11):E745–U584

25.

Shimizu N, Tsujimura A, Akino H et al (2012) Imidafenacin reduces night time urine production as well as increase bladder capacity in nocturia with BPH and concomitant OAB. Results from prospective randomized controlled trial, GOOD-NIGHT study. Abs. 432 ICS

26.

Wada N, Watanabe M, Kita M et al (2012) Effect of imidafenacin on nocturia and sleep disorder in patients with overactive bladder. Urol Int 89(2):215–221CrossRefPubMed

27.

Kase H, Arak S, Kitamura T et al (2010) A comparative study of anticholinergic drugs used for overactive bladder in routine clinical practice, with a focus on dry mouth. Jpn J Urol Surg 23:1299–1306

28.

Homma Y, Yamaguchi O, Imidafenacin Study Group (2008) Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 15:986–991CrossRefPubMed

Titel: Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis
verfasst von: Wei Huang
Huantao Zong
Xin Zhou
Yong Zhang
Publikationsdatum: 01.03.2015
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 3/2015
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-015-0916-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Prevalence and determinants of interatrial block in hemodialysis patients

The importance of calciuria as lithogenic factors in patients with osteopenia/osteoporosis

Does metabolic syndrome increase the risk of infective complications after prostate biopsy? A critical evaluation

Laparoscopic retroperitoneal radical nephrectomy in a pregnant woman with retrocaval artery

Depressive symptoms in patients diagnosed with benign prostatic hyperplasia

Use of the nuclear matrix protein 22 Bladder Chek test™ in the diagnosis of residual urothelial cancer before a second transurethral resection of bladder cancer